Related references
Note: Only part of the references are listed.Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
I. N. Bruce et al.
LUPUS (2016)
Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
C. E. Collins et al.
LUPUS SCIENCE & MEDICINE (2016)
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
Margherita Zen et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
Joyce S. Hui-Yuen et al.
JOURNAL OF RHEUMATOLOGY (2015)
Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight
A. Doria et al.
LUPUS (2015)
Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis
Francesca Pierotti et al.
PLOS ONE (2015)
Annual direct medical cost of active systemic lupus erythematosus in five European countries
Andrea Doria et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOUS (SLE) PATIENTS TREATED WITH BELIMUMAB IN CLINICAL PRACTICE SETTINGS: RESULTS FROM THE OBSERVE STUDY IN GERMANY
A. Schwarting et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Patterns of systemic lupus erythematosus expression in Europe
R. Cervera et al.
AUTOIMMUNITY REVIEWS (2014)
Optimizing outcome in SLE: treating-to-target and definition of treatment goals
Andrea Doria et al.
AUTOIMMUNITY REVIEWS (2014)
In-/off-label use of biologic therapy in systemic lupus erythematosus
Mariele Gatto et al.
BMC MEDICINE (2014)
Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: A new anti-BLyS human monoclonal antibody
Husein Husein-ElAhmed et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2014)
Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment
M. Jueptner et al.
LUPUS (2014)
Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report
Abhijeet Danve et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
EVALUATION OF USE OF BELIMUMAB IN CLINICAL PRACTICE SETTINGS (OBSERVE STUDY) IN SPAIN: HEALTH RESOURCE UTILIZATION AND LABOUR ABSENTEEISM
J. Cortes et al.
VALUE IN HEALTH (2014)
Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Maria Lucia Specchia et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Real life experience on the effect of Belimumab in patients with active systemic lupus
Morton Scheinberg et al.
SPRINGERPLUS (2014)
Long-term complications of past glucocorticoid use
Luciana P. C. Seguro et al.
AUTOIMMUNITY REVIEWS (2013)
Emerging and critical issues in the pathogenesis of lupus
Mariele Gatto et al.
AUTOIMMUNITY REVIEWS (2013)
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
D. J. Wallace et al.
LUPUS (2013)
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
M. A. Dooley et al.
LUPUS (2013)
Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman
E. E. Fliesser et al.
LUPUS (2013)
Premature coronary heart disease in SLE: can we prevent progression?
L. Iaccarino et al.
LUPUS (2013)
Global trends, potential mechanisms and early detection of organ damage in SLE
Anselm Mak et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort
Rekha Lopez et al.
RHEUMATOLOGY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome
Amanda J. Steiman et al.
JOURNAL OF RHEUMATOLOGY (2010)
Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus
J. Nossent et al.
LUPUS (2010)
Cutaneous Lupus Erythematosus Issues in Diagnosis and Treatment
Hobart W. Walling et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2009)
Prednisone, Lupus Activity, and Permanent Organ Damage
Mae Thamer et al.
JOURNAL OF RHEUMATOLOGY (2009)
Long-term prognosis and causes of death in systemic lupus erythematosus
Andrea Doria et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus
K Manger et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus
P Rahman et al.
LUPUS (2001)
Prognostic parameters for flare in systemic lupus erythematosus
MJ Mirzayan et al.
RHEUMATOLOGY (2000)
Share Paper
